A genetically modified *Plasmodium berghei* parasite as a surrogate for whole-sporozoite vaccination against *P. vivax* malaria

Diana Moita, Teresa G. Maia, Miguel Duarte, Carolina M. Andrade, Inês S. Albuquerque, Ankit Dwivedi, Joana C. Silva, Lilia González-Céron, Chris J. Janse, António M. Mendes and Miguel Prudêncio

Two malaria parasite species, *Plasmodium falciparum* (Pf) and *P. vivax* (Pv) are responsible for most of the disease burden caused by malaria. Vaccine development against this disease has focused mainly on Pf. Whole-sporozoite (WSp) vaccination, targeting pre-erythrocytic (PE) parasite stages, is a promising strategy for immunization against malaria and several PWSp-based vaccine candidates are currently undergoing clinical evaluation. In contrast, no WSp candidates have been developed for Pv, mainly due to constraints in the production of Pv sporozoites in the laboratory. Recently, we developed a novel approach for WSp vaccination against Pf based on the use of transgenic rodent *P. berghei* (Pb) sporozoites expressing immunogens of this human-infective parasite. We showed that this platform can be used to deliver PE Pf antigens, eliciting both targeted humoral responses and cross-species cellular immune responses against Pf. Here we explored this WSp platform for the delivery of Pv antigens. As the Pv circumsporozoite protein (CSP) is a leading vaccine candidate antigen, we generated a transgenic Pb parasite, PbviVac, that, in addition to its endogenous PbCSP, expresses PvCSP under the control of a strictly PE promoter. Immunofluorescence microscopy analyses confirmed that both the PbCSP and the PvCSP antigens are expressed in PbviVac sporozoites and liver stages and that PbviVac sporozoite infectivity of hepatic cells is similar to that of its wild-type Pb counterpart. Immunization of mice with PbviVac sporozoites elicits the production of anti-PvCSP antibodies that efficiently recognize and bind to Pv sporozoites. Our results warrant further development and evaluation of PbviVac as a surrogate for WSp vaccination against Pv malaria.

**INTRODUCTION**

Malaria prevails as one of the deadliest infectious diseases worldwide, remaining a major public health concern, especially in the tropical and subtropical regions. In 2020 alone, the World Health Organization (WHO) estimated 241 million new clinical cases and 627,000 malaria-associated deaths, with the WHO African and Southeast Asian regions accounting for most global malaria cases. In humans, malaria can be caused by several Plasmodium species, but *P. falciparum* (Pf) and *P. vivax* (Pv) are still responsible for most of the disease burden worldwide. Although Pf remains the deadliest malaria parasite, Pv is the most geographically widespread, and is increasingly recognized as a cause of severe disease.

Mammalian infection by malaria parasites is initiated when an infected *Anopheles* mosquito deposits *Plasmodium* sporozoites, the parasite’s liver-infective forms, into the host’s skin and skin vasculature. Sporozoites then travel to the liver, where they infect hepatocytes and initiate an asymptomatic phase of asexual replication and parasite growth. This process culminates in the formation of thousands of parasites, which are released into the bloodstream, where they invade, asexually replicate, egress, and reinvoke host erythrocytes, in a continuous cycle that is responsible for malaria symptoms. Importantly, unlike Pf, Pv parasites can generate dormant liver forms, termed hypnozoites, which may reactivate and lead to disease relapses long after the initial mosquito bite.

Vaccines targeting the pre-erythrocytic (PE) stages of *Plasmodium* parasites, i.e., sporozoites and liver stages, constitute the most attractive approach to prevent malaria and are still the primary vaccination strategy to tackle Pf (reviewed in). Recently, the WHO recommended the administration of the subunit vaccine RTS,S/AS01 (RTS,S) to children living in regions of moderate-to-high malaria transmission. RTS,S specifically targets the Pf circumsporozoite protein (CSP), the most abundant antigen on the sporozoite surface. This vaccine demonstrated ~30% reduction in severe malaria cases in phase 3 clinical trials performed in African countries. Nonetheless, RTS,S’s relatively low and short-lived efficacy underscores the need to develop vaccines with higher and more durable protection. An alternative to subunit vaccines is the use of whole-sporozoite (WSp) immunization strategies, based on the administration of live attenuated *Plasmodium* sporozoites to induce efficient immune responses against the PE parasite stages, precluding erythrocytic infection and, thus, clinical symptoms and further transmission. These include radiation-attenuated sporozoites, genetically-attenuated parasites and immunization with fully infectious parasites under chemoprophylaxis. Such systems have successfully been developed for Pf vaccination, with promising results in the clinic. Conversely, the most advanced candidate for vaccination against Pv is still in early stages of clinical development, and progress made in the development of Pf WSp vaccines is far from achieved for Pv. In fact, these vaccines depend on the availability of *Plasmodium* sporozoites, the liver-infective form of malaria.
parasites, and while Pf sporozoites can be easily obtained under laboratory conditions, it is currently impossible to successfully maintain in vitro blood stage cultures of Pv for long periods of time. Since Pv sporozoites can only be obtained from mosquitoes fed on Pv-infected blood, their availability depends on blood samples collected from naturally infected patients, curtailing the possibilities of developing Pv sporozoite-based vaccines. As such, attempts at developing WSP vaccines against Pv are scarce, and no Pv WSP candidates have been clinically evaluated, leaving this important gap largely unaddressed.

Recently, we developed an alternative WSP vaccination approach based on the use of genetically modified rodent P. berghei (Pb) sporozoites as a platform to elicit cross-species immune responses, as well as deliver antigens of human-infective parasites, eliciting specific immune responses against the latter. We have shown that Pb parasites are inherently safe for human use, as they are unable to develop in human erythrocytes, in what would be the symptomatic stage of the parasite’s life cycle. In a phase 1/2a clinical trial, PbVac, a Pb parasite engineered to express the PfCSP, was shown to induce cross-species cellular immune responses and functional antibodies against Pf, leading to an estimated 95% reduction in the Pf liver load of immunized volunteers at the dose employed.

The clinical validation of the Pb-based WSP immunization strategy warranted the exploitation of the Pb platform for the delivery of Pv antigens. Since the PvCSP is a leading vaccine candidate (reviewed in and we now constructed PbviVac, a genetically modified Pb parasite that expresses PvCSP, to be employed as a surrogate for WSP vaccination. Here, we describe the generation and pre-clinical characterization of PbviVac, showing that it retains the mosquito and hepatic infectivity levels of the parental Pb line. We further demonstrate that immunization of rodents with PbviVac elicits the production of antibodies that efficiently recognize and bind to Pv sporozoites, validating the novel parasite line as a tool to potentially be employed for immunization against Pv malaria.

RESULTS

Amplification and sequence comparison of the PvCSP gene

In order to generate a transgenic Pb line that expresses a leading vaccine candidate antigen, PvCSP, the PvCSP coding sequence of a Pv field isolate from Thailand was initially amplified and compared to reference PvCSP sequences, including those of Pv strains P01 and Sal-1 and Supplementary Fig. 1. As expected, the coding regions of both the N- and C-termini were highly conserved among the different PvCSP sequences, with a single non-synonymous polymorphic site at position 38, resulting in a transition from an asparagine to a glycine in the Pv Thailand isolate (Supplementary Fig. 1), while most variability occurred in the protein’s central repeat region (Fig. 1). Our results indicate that the sequence of the PvCSP gene present in the Thailand field isolate employed in our study is similar to that of the most common and well-adapted variant of the PvCSP protein, VK210. This isolate presents 16 repeats of the VK210 variant’s most conserved peptide repeat motifs, GDRAD(G/A)QPA, as well as a single occurrence of two other repeat motifs, GARADGQPA and GNGAGGQAA, the latter of which is also found in Pv strain Sal-1, as well as in Sri Lanka’s and Brazil’s Pv populations.

Generation of the PbviVac parasite line

A transgenic Pb line that expresses PvCSP in addition to its endogenous PbCSP, termed PbviVac, was generated using the GIMO method of transfection, as previously described for PbVac (Supplementary Fig. 2A). Briefly, the transgenic GIMO/Panka line (hereafter referred to as Pbowt), containing a positive-negative selection marker (hdhfr: yfcu) stably integrated into the silent 230p locus, was transfected by double cross-over homologous recombination with a plasmid containing the PvCSP-encoding gene fused to the 230p targeting region. This resulted in the replacement of the selection marker by the PvCSP gene and in its insertion into the 230p locus of the Pb genome under the control of the 5′- and 3′-regulatory sequences of the Pbis4 gene, which is expressed exclusively in infective sporozoites and developing liver stages.

Following transfection, a clonal population was obtained by negative selection of a single transfected parasite employing the S-fluorocytosine (S-FC) drug (Supplementary Fig. 2A). Clonal expansion resulted in two independent clones, PbviVac #11 and #12, selected for further analysis. The correct integration of the PvCSP expression cassette into the inert 230p locus, as shown by the absence of the hdhfr: yfcu selection marker, and the correct integration of the construct into the genome, were confirmed through genotyping analysis by diagnostic PCR analysis of both PbviVac clones (Supplementary Fig. 2B).

Production of PvCSP-expressing sporozoites by PbviVac

Since relatively high numbers of sporozoites are required to elicit sterile immunity against malaria employing WSP vaccines, we assessed the potential impact of the genetic manipulation of the Pb parasite on the sporogonic development of PbviVac. To this end, midgut oocyst and salivary gland sporozoite numbers in mosquitoes fed on the blood of PbviVac-infected mice were quantified 10 and 20–22 days after mosquito infection, respectively. Our results show that the PbWT and PbviVac parasite lines present comparable numbers of oocysts (Fig. 2A) and sporozoites (Fig. 2B) in the mosquito host’s midgut and salivary glands, respectively, indicating that the insertion of the PvCSP gene in the Pb genome did not significantly impact the resulting transgenic parasite’s mosquito infectivity. We then analysed the expression of the endogenous PbCSP and heterologous PvCSP by PbviVac sporozoites. Immunofluorescence microscopy analysis confirmed that while only PbCSP is expressed by control PbWT sporozoites, PbviVac parasites express both PbCSP and PvCSP, as expected from the placement of the PvCSP gene under the control of the PE Pbis4 promoter (Fig. 2C).

In vitro and in vivo hepatic infection by PbviVac parasites

Having shown that the sporogonic development of the PbviVac parasite was not impaired by the transgenesis procedure employed in its generation, we then sought to evaluate the parasite’s hepatic infectivity in vitro employing the HepG2 and HuH7 human hepatoma cell lines. Immunofluorescence microscopy analysis (IFA) of infected HepG2 cells revealed that the

npj Vaccines (2022) 163

Published in partnership with the Sealy Institute for Vaccine Sciences
infection rates (Fig. 3A) and hepatic parasite area at 48 h post-infection (hpi) (Fig. 3B) of both clones of the \textit{Pb}viVac parasite are similar to those of \textit{Pb}WT. Our data further showed that both \textit{Pb}CSP and \textit{PvCSP} are expressed by developing hepatic \textit{Pb}viVac parasites and are present at the parasite’s parasitophorous vacuole membrane (PVM), while, as expected, \textit{Pb}WT parasites only express \textit{PbCSP} (Supplementary Fig. 3). Similar results were obtained following infection of Huh7 cells (Supplementary Fig. 2A–C).

We next sought to evaluate the liver infectivity of both parasite lines in vivo, employing the C57BL/6J mouse model. Quantitative real-time PCR (qPCR) and IFA of livers from infected mice revealed similar overall infection loads for \textit{Pb}viVac and \textit{Pb}WT (Fig. 3C), with equivalent numbers of exoerythrocytic forms (EEFs) (Fig. 3D) and identical in vivo development (Fig. 3E). IFA of infected liver sections further showed that both \textit{Pb}CSP and \textit{PvCSP} are expressed at the PVM during the liver stage of parasite development (Fig. 3F).

Altogether, our analyses showed that \textit{Pb}viVac parasites infect and develop inside hepatocytes similarly to the \textit{Pb}WT control parasites, and that they express the heterologous \textit{PvCSP} throughout their PE development.

**DISCUSSION**

Although the overall incidence of malaria cases associated with \textit{Pf} has been declining outside Sub-Saharan, the prevalence of cases due to \textit{Pv} is increasing, with this parasite species likely persisting as an obstacle to malaria eradication in the absence of an effective vaccine, which remains unavailable\textsuperscript{38}. However, and in contrast to \textit{Pf}, only very few \textit{Pv} vaccine candidates have progressed to clinical evaluation. They include synthetic peptides, recombinant proteins and chimeric constructs comprising the N- and C-terminal regions as well as the central repeat region of the CSP (reviewed in\textsuperscript{29}). One of the most advanced candidates, the Vivax malaria protein 1 (VMP001) vaccine, is a chimeric protein produced in *Escherichia coli*.
coli that comprises a truncated repeat region containing repeat sequences of the two most common Pv strains, VK210 and VK247. In a phase 1/2a clinical trial, VMP001 demonstrated to be safe and induced strong humoral and CD4+ T cell immune responses to the vaccine antigen, resulting in a significant delay in patentcy15. More recently, a combination of three long synthetic peptides corresponding to the N-terminal, central repeats from the VK210 variant and C-terminal regions of the Pv CSP was evaluated in a phase 2a/2b clinical trial, revealing significant protection and immunogenicity in both naïve and semi-immune volunteers30.

Alternatively, WSp immunization approaches present a broader array of antigens to the immune system, potentially widening the range of immune responses elicited by vaccination. However, a Pv-based WSp vaccine remains unavailable, not least because the establishment of a robust system for in vitro culture of Pv has been hindered by several technical and logistical limitations that challenge not only vaccine production but also the future assessment of its efficacy in controlled human malaria infection (CHMI) trials11. Efforts to develop blood stage CHMI using Pv stabilities are currently ongoing and the blood of recipients can be used for mosquito feeds for Pv sporozoite generation. Nevertheless, although significant advances in the establishment of reproducible Pv CHMIs have been reported35,36, and the first trial to assess the efficacy of a PvCSP vaccine candidate by CHMI was already successfully undertaken15, these are still dependent on the availability of blood from naturally infected patients to produce Pv sporozoites, and must take into account the need for elimination of hypnozoites.

Our study proposes an innovative approach to PE WSp vaccination against Pv that may help circumvent current limitations in production of Pv sporozoites in the laboratory16. The promising results obtained in a phase 1/2a clinical trial with the PbVac PE WSp vaccine candidate19, encouraged us to explore a similar strategy to deliver Pv antigens for immunization against this human-infective parasite. PbVac thus constitutes a potential surrogate for WSp immunization against Pv malaria, that is able to induce antibody immune responses against Pv CSP, as well as, potentially, cross-species cellular immunity targeting antigens conserved between the rodent and human malaria parasites33,34.

Protection induced by WSp vaccines targeting pre-erythrocytic stages has been reported to be mediated by both T cells and antibodies (reviewed in33). A possible advantage of the expression of Pv antigens by Pb relative to their incorporation in subunit vaccines is that a Plasmodium-based expression platform likely favours the correct folding of full-length Pv proteins, which may enhance the quality, quantity, and the repertoire of immune responses elicited by immunization35,36. Indeed, our results show

Fig. 3  *PbviVac* in vitro and in vivo pre-erythrocytic development and expression of *PvCSP*. A, B Compared in vitro infectivity and parasite development of *PbWT* and *PbviVac* parasites in HepG2 human hepatoma cells (*n* ≥ 3 coverslips per group); Compared in vivo infectivity and development of *PbWT* and *PbviVac* parasites as determined by qPCR analysis of infected mouse livers (C), quantification of the number of parasites per liver area (D), and development of hepatic parasites (E) (*n* = 3 mice per group); (F) Representative immunofluorescence microscopy images of *PbWT* and *PbviVac* parasites developing in mouse livers 48 hpi. Immunofluorescence staining with the anti-PvCSP (green) and anti-PvCSP VK210 (yellow), as well as with anti-PbUIS4 antibodies, confirms the expression of both proteins by *PbviVac* and their localization to the parasite membrane. Scale bar: 20 µm. Measurements were taken from distinct samples. The boxes correspond to the 25th and 75th percentiles in (A) and (D) and the black lines/bars and grey lines correspond to mean and standard error of the mean, respectively (ns: not significant, Mann–Whitney U test).
that immunization of mice with PbviVac elicits the production of anti-PvCSP antibodies that efficiently recognize and bind to Pv sporozoites. This observation, alongside our ELISA data showing that these humoral responses include antibodies that specifically recognize the PvCSP repeat region, suggest that they have the functional ability to inhibit hepatic infection by Pv sporozoites, similarly to what was observed for PbVac and Pf. On the other hand, our in silico data reveal a high degree of CD8+ T cell epitope similarity between Pb and Pv, raising the possibility that immunization with PbviVac might elicit some level of cellular immunity against Pv, as was observed for PbVac and Pf. However, this possibility still requires experimental verification, which would add valuable information regarding the immunogenicity of this potential vaccine candidate and might constitute an important step on its path to the clinic.

PbviVac expresses the PvCSP from a Thailand field isolate, whose N- and C-terminal regions are highly conserved among multiple PvCSP sequences, and are i) responsible for both CSP-specific and non-specific T cell and antibody responses, and ii) contain the TSR motif and region I, which are critical for invasion and protein conformational changes throughout the parasite’s development. Contrarily to Pf, the repeat region of the PvCSP exhibits genetic heterogeneity indicating that a vaccine targeting only one Pv strain could lead to strain-specific immune responses, leaving populations susceptible to infection with the other circulating variants. Thus, although VK210 is the most common variant of PvCSP, the expression of only this sequence on the Pb platform may represent a limitation of PbviVac. In fact, a recombinant protein including the repeats of both PvCSP VK210 and VK247, as well as of P. vivax-like CSP, has recently been generated and shown to elicit the production of high titer antibodies against each of the variants following immunization of a mouse model. Accordingly, and since previous studies demonstrated the absence of significant cross-reactivity among the different PvCSP alleles in animals immunized with individual recombinant proteins (VK210, VK247 and P. vivax-like), the Pb platform may in the future be engineered to simultaneously express of the most common alleles of CSP, potentially eliciting protective immune responses against a wider range of Pv strains.

Vaccination approaches based on Pb parasites are inherently safe and versatile, given this parasite’s high amenability to genetic modification. Since the presence of several neutral loci in the Pb genome enables the insertion of Pv genes besides CSP, future candidates may be designed to express not only additional PE antigens, such as the thrombospondin-related anonymous protein (TRAP) but also candidate immunogens from different stages of this parasite’s life cycle, such as the blood stage Duffy binding protein (DBP) or the transmission stage Pvs25 protein. Thus, our results establish not only a pre-clinical proof-of-concept for Pb-based vaccination against Pv, but also pave the way for the evaluation of PbviVac or other candidates expressing additional Pv antigens in the clinic. Naturally, in order to be suitable for human vaccination, such candidates need to be produced under good manufacturing procedures (GMP) conditions. Since blood stage cultures of rodent malaria parasites have not yet been established, this could be achieved by feeding mosquitoes on infected Specific Pathogen Free rodents, followed by sporozoite purification and cryopreservation using the methods developed and established by Sanaria, Inc.

In conclusion, our study shows for the first time that genetically engineered Pb parasites expressing Pv antigens may constitute a viable alternative to Pb-based WSP vaccines, overcoming the current limitations in producing GMP-compliant Pv sporozoites in the quantities required for vaccination.

METHODS

Animal experimental procedures

All animal experiments were performed at the animal Facility of Instituto de Medicina Molecular João Lobo Antunes. Male C57BL/6J mice, aged six to eight weeks, were purchased from Charles River Laboratories (Lyon, France) and housed under specific pathogen-free (SPF) conditions. Experimental procedures were performed according to the Federation of European Laboratory Animal Science Associations (FELASA) guidelines and approved by IMM-JLA’s animal ethics committee (ORBEA-IMM). Mice were kept under a 12 h light/dark period at a temperature of 25 °C and 40–70% relative humidity. Filtered tap water and y-irradiated pelleted diet were provided ad libitum.

Parasite lines

The GIMO_PbhMKn (henceforth referred to as P6WT) mother line, which contains the human dihydrofolate reductase:yeast cytosine deaminase and uridylic phosphoribosyl transferase (hdhfr:yfcu) positive-negative selection markers in the silent 230p locus, was employed to produce the two clonal lines of the transgenic PbviVac parasite through the ‘gene insertion/marker out’ (GIMO) transfection method, as described below.

Generation and genotyping of transgenic P. berghei parasite, PbviVac

A transgenic Pb parasite line containing a PvCSP expression cassette in the silent 230p locus was generated using the GIMO technology. A PvCSP expression cassette was generated containing a PvCSP coding sequence from a Pv isolate from Thailand and confirmed by sequencing (Supplementary Fig. 1; Stabvida sequencing services).
The PvCSP coding sequence is flanked by the S' and 3' promoter and transcription terminator sequences of Pfbs4i5, which were amplified from wild-type Pb ANKA (PbWT) genomic DNA. The GIMO technology was used to integrate by double crossover homologous recombination into the neutral 230p locus of the GIMO-malaria mother line, replacing the positive-negative selection marker hdhfr/ycfu cassette in the PbWT mother line with the PvCSP expression cassette (Supplementary Fig. 2). Transfected parasites were selected in vivo by applying negative selection by providing 5-fluorocytosine (5-FC) in the drinking water of mice. Selected transgenic parasites were cloned by the method of limiting dilution and two independent clones were selected for further characterization and analysis (PbviVac #1 and PbviVac #12). Correct integration of the construct into the genome of transgenic parasites was analysed by diagnostic PCR analysis of gDNA (Supplementary Fig. 2B) using the following primers sequence: GCAAAGTGAGTGGCATAATGC; p1494: AATTAGTTGGGATCCATATGC; p1901: GTTGCGAATATGCATGC; p1902: GTTTAGGATGCGAATAGACG; p1497: TATAATCCATTATGAGTAGTGAACATCTTACG; p1655: GAAATCGCAACAACTAATGATC.

Mosquito infection and oocyst count
Anopheles (A.) stephensi mosquitoes were reared at iMM JLA-Lisboa at 27 °C and 80% humidity. Gametocyte-carrying infected mice were anesthetized and placed on top of a cage with previously starved female mosquitoes for about 30 min to allow mosquito biting. After the feeding, mosquitoes were incubated at 21 °C and 80% humidity and in a 12 h light/dark cycle. Ten days after infectious blood meal, mosquito midguts were hand-dissected and mounted in a glass microscope slide with 0.1% mercurochrome. Oocysts were then counted using an Olympus CKX41 inverted microscope.

Sporozoite collection and imaging
Huh7 and HepG2 cells from human hepatoma cell lines were cultured in RPMI medium supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) Penicillin/Streptomycin, 1% (v/v) Glutamine, 1% (v/v) non-essential amino acids and 1% (v/v) 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), pH 7 and maintained at 37 °C with 5% CO2. For immunofluorescence microscopy analyses, cells were seeded (5 x 104 per well) on glass coverslips in 24-well plates and infected 24 h later by adding 3 x 104 freshly dissected sporozoites in supplemented RPMI containing Fungizone (1 μg/mL) and Gentamicin (50 μg/mL). Sporozoite addition was followed by centrifugation at 1800 x g for 5 min. Medium was replaced approximately 2 h post-infection (hpi) by fresh medium. Forty-eight hpi, cells were fixed with 4% (v/v) PFA for 20 min at RT and stored at 4 °C in PBS. Cells were incubated with the permeabilization/blocking solution (0.1% v/v Triton X-100, 1% w/v bovine serum albumin (BSA) in 1x PBS) for 30 min at RT. Parasites were stained with a Pb-specific goat anti-PbUIS4 (1:450 dilution of a 2 mg/ml stock), Pb-specific mouse anti-PbCSP (mAb 3D11; 1:1200 dilution) or Pv-specific mouse anti-PvCSP (mAb 2F2; 1:500 dilution) antibodies for 1 h at RT, followed by three washes with permeabilization/blocking solution. Cells were then incubated in a 1:300 dilution of anti-mouse Alexa-Fluor 488 (Jackson ImmunoResearch Laboratories) and anti-Goat Alexa-Fluor 555 (ThermoFisher) in the presence of 1:1000 dilution of Hoechst 33342 (Invitrogen) for nuclei staining. After 3 washes with PBS, coverslips were mounted in microscope slides with Fluoromount G (SouthernBiotech) and a cover slide. Confocal images were acquired using a Zeiss LSM 710 confocal microscope. Widefield images for exoezymic form (EEFs) counting and parasite size determination were acquired on a Zeiss Axiovert 200 M widefield fluorescence microscope. Images were processed with ImageJ software (version 1.49b).

In vivo infection of C57BL/6J mice and liver collection
C57BL/6J mice were infected intravenously (i.v.), through retro-orbital injection of 3 x 106 freshly collected sporozoites. Mice were collected at 48 hpi with the left lobes being snap-frozen in liquid nitrogen and stored at −80 °C for subsequent analysis; the remaining lobes were fixed on 4% PFA and stored at 4 °C for immunofluorescence microscopy analysis.

RNA extraction, cDNA synthesis and qPCR analysis of hepatic infection
Liver lobes collected for qPCR analysis were homogenized in 3 mL of denaturing solution (4 M guanidine thiocyanate; 25 mM sodium citrate pH 7; 0.5% w/v N-lauroylsarcosine and 0.7% v/v β-mercaptoethanol in DEP-treated water). Total RNA was extracted from liver homogenates using the Qiagen RNA extraction kit, according to the manufacturer’s instructions. The concentration of RNA in each sample was assessed by measurement of absorbance at 260 nm on a NanoDrop 2000 spectrophotometer. Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the NZYTech First-Strand cDNA synthesis kit, according to the manufacturer’s instructions. The cDNA was synthesized in a Biometra Personal thermocycler employing the following parameters: 25 °C for 10 min, 55 °C for 30 min and 85 °C for 5 min. The qPCR reaction was performed in a total volume of 20 μL in an ABI Prism 7500 Fast system (Applied Biosystems) using the SYBR® Green Real-Time PCR Master Mix (BioRad). Parasite load was quantified using primers specific to Pb 18S rRNA (forward/reverse: AACACATTAAATAGGCATTACATCCTACATC/ GGAGATTGTTTGGACGTATGTG). Mouse housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (Hprt) expression was used for normalization (forward/reverse: TTGCTAGCCTCTGCGATTACATCC/ CAAAGCATTATTTCCGATTTG). Analysis of qPCR data was performed using the delta-delta relative quantification method.

Immunofluorescence staining of liver sections
All experiments were performed at the Bioimaging Facility of Instituto de Medicina Molecular João Lobo Antunes. PFA-fixed liver lobes were cut into 50 μm sections using a vibratome (VT1000S, Leica) and were incubated in permeabilization/blocking solution (1% w/v BSA, 0.5% v/v Triton X-100 in PBS 1x) and IgG anti-mouse (1:150) at RT overnight. After 3 washes with PBS, liver sections were incubated for 2 h with a Pb-specific goat anti-PbUIS4 (1:450 dilution of a 2 mg/ml stock) and mouse anti-PbCSP (mAb 3D11; 1:200 dilution) or mouse anti-PvCSP (mAb 2F2; 1:500 dilution) antibodies. Following primary antibody incubation, sections were washed thrice with PBS 1x and incubated with...
the following secondary antibodies: 1:500 dilution of anti-mouse Alexa-Fluor 488 (Jackson ImmunoResearch Laboratories), 1:500 dilution of anti-goat Alexa-Fluor 555 (Thermofisher) and 1:50 dilution of Alexa-Fluor 660 Phalloidin (Thermofisher) for actin staining in the presence of 1:150 dilution of Hoechst 33342 (Invitrogen). After washing, the liver sections were mounted on microscope slides with Fluoromount G (SouthernBiotech). Wide-field images for hepatic infection and parasite size determination were acquired in a Zeiss Axiosvert 200 M microscope. Confocal images were acquired using a Zeiss LSM 710 confocal microscope. Images were processed with ImageJ software (version 1.49b).

Immunization of C57BL/6 J mice

In order to analyse the humoral responses elicited by PbvivVac parasites, C57BL/6 J mice were immunized i.v., through three intravenous retro-orbital injections of 1 x 10^6 freshly collected sporozoites from either PbWT or PbivVac parasite lines or with an extract obtained from the dissection of an identical number of non-infected mosquito salivary glands, with one-week intervals between immunizations and daily administration of chloroquine (35 mg/kg/mouse weight) to prevent the establishment of blood stage infection. Before each immunization and one week after the final one, blood was collected and centrifuged at 10,000 x g for 10 min to separate the red blood cells from the plasma. Plasma was then stored at −80 °C until further analysis either by ELISA or IFA.

ELISA for anti-PbCSP and anti-PvCSP antibodies

High protein-binding capacity 96-well enzyme-linked immunosorbent assay (ELISA) plates (Nunc MaxiSorp™ flat-bottom) were coated with synthetic peptide (Sigma) based on the VK210 variant repeat region of PvCSP with the amino acid sequence GD RAD GOP A52 QGP A52, or the repeat region of the PbCSP with the amino acid sequence CPPPPNPN2. The peptide was coated overnight at 4 °C at a concentration of 5 μg/ml in a volume of 50 μl per well. Plates were washed three times with PBS containing 0.1% (v/v) Tween-20 and blocked with 200 μl PBS containing 0.1% (v/v) Tween-20 and 1% (w/v) BSA for 30 min at RT. Plates were washed one additional time and samples serially diluted in PBS containing 0.1% (v/v) Tween-20 and 1% (w/v) BSA were added and incubated at 22 °C for 2 h. After washing four times, horseradish peroxidase-labelled goat anti-mouse IgG (GE Healthcare UK) was added at a dilution of 1:2000 and incubated at 22 °C for 1 h. BD OptEIA™ TMBSubstrate Reagent was then added for development and incubated for 1 to 3 min at 22 °C before stopping the reaction by adding 50 μl Stop solution (2NH2SO4). The optical density was determined using a microplate reader (Infinite M200). To serve as a positive control and to allow comparison between samples from different assays, a standard titration curve of at least 8 points, starting at a dilution of 1/20, was used as reference in all assays.

Immunofluorescence analysis on immobilized Pv sporozoites

Pv salivary gland sporozoites were obtained from infected Anopheles albimanus mosquitoes, 12–14 days after artificial blood feeding through parafilm membranes on Pv-infected blood82,93. About 1000 sporozoites were added per well in 8-well slides, air-dried, and preserved at −80 °C until used. IFA slides containing Pv VK210 sporozoites were thawed and air-dried. Blocking was done with PBS containing 3% (w/v) BSA. After washing with PBS containing 0.5% (w/v) BSA, mouse plasma was added in serial dilutions ranging from 1:40 to 1:400 overnight at 4 °C, followed by extensive washing with PBS containing 0.05% (w/v) Tween-20. FITC anti-mouse IgG+I-M (1:500; Invitrogen) was used as secondary fluorescent antibody and incubated for 1 h at RT. After washing three times with PBS containing 0.05% (w/v) Tween 20, slides were mounted in buffered glycerine and analysed by fluorescence microscopy using a Zeiss UV microscope. PBS was used as a negative control and two monoclonal antibodies against native PvCSP repeats were used as positive controls in every slide. The negative control did not deliver any IFA signal detectable by visual examination, even at the lowest dilution.

In silico identification of CD8+ T cell epitopes in the Pv and Pb proteomes

CD8+ T cell epitopes were predicted in the proteomes of P. berghei ANKARA (5,076 proteins) and P. vivax strains Sal 1 (5,585 proteins) and P01 (6,677 proteins) using the in silico epitope predictor netMHCpan (v4.0)84, as previously described17, Briefly, HLA types were chosen to represent 10 of the most frequent HLA-A and B supertypes, based on allele frequencies taken from the Allele Frequency Net Database53. Peptide lengths of 9,10, and 11 were used to search for 9-mer core epitopes. Strong binders, defined as peptides that are in the top 0.5% of binding affinity prediction scores, are reported here.

Statistical analyses

Statistical analyses were performed using the GraphPad Prism 5 software. Results are expressed by mean ± SEM and statistical analyses were performed using the Mann-Whitney non-parametric test.

REFERENCES


ACKNOWLEDGMENTS
We would like to thank the bioimaging and rodent facilities of Instituto de Medicina Molecular João Lobo Antunes for their technical support. The authors would like to acknowledge Ana Filipa Teixeira for mosquito production and infection, Prof. Jetsumon Prachumsi for providing the Pv field isolate from Thailand, and Dr. Shahid M. Khan for invaluable discussions and pivotal insights. A.D. and J.C.S. were supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (U19AI10820 and R01AI14900). A.M.M. acknowledges Fundação para a Ciência e Tecnologia, Portugal (FCT) for Grant PTDC-BBB-BMD-2695-2014. M.P. acknowledges the “la Caixa” Foundation for Grant HR21-841, the GSK OpenLab Foundation for grant TC269, and FCT for grant PTDC-SAU-INF-29550-2017. D.M. acknowledges FCT for grant SFRH/BD/148817/2019.

AUTHOR CONTRIBUTIONS
D.M. contributed to the experimental design, carried out experimental work, analyzed data, and co-wrote the manuscript. T.M., M.D.A. and I.A. carried out the experimental work and analysis. A.D. and J.C.S. carried out the silico analysis. L.G.C. carried out immunofluorescence analysis. C.J.J. provided crucial biological materials and intellectual input. A.M.M. contributed to the experimental design, carried out and co-supervised the experimental work, produced the figures, and co-wrote the manuscript. M.P. coordinated the study, contributed to the experimental design, supervised the experimental work, and co-wrote the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS
A.M.M. and M.P. are inventors on a patent or patent application issued, allowed or filed internationally, covering parts of this work. All other authors declare no competing interests.